14 results about "Pyrimidine" patented technology

A pyrrolo[3,2-d]pyrimidine compound, such as a compound of the formula (I):

or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.

A compound having the structure of Formula II, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt thereof:

The compound is useful as CFTR modulator. Further, a method of using the compound and pharmaceutical composition comprising the compound are provided for treating diseases in lungs, pancreas, gastrointestinal system, sinuses, reproductive system, and the sweat glands.

The invention relates to the technical field of pharmaceutical preparations and discloses a rosuvastatin calcium tablet. [4-[4-fluorophenyl-6-(1-methylethyl)-2-[N_ methyl-(N-methylsulfonyl) amino]-5-pyrimidyl] methyltriphenylphosphonium bromide, (4R-cis)-6-formyl-2, 2-dimethyl-1, 3-dioxane-4-cyclopentyl acetate, potassium carbonate, dimethyl sulfoxide, methylbenzene, acetonitrile, ethyl acetate, methanol, isopropanol, sodium hydroxide, sodium chloride and calcium chloride. According to the rosuvastatin calcium tablet and the preparation process thereof, a plurality of experiments prove that: when reaction temperature is about 75 DEG C in intermediate synthesis, alkali is the optimal experimental condition of the potassium carbonate, and reaction raw materials can react completely, the generation of multiple impurities is prevented, productivity can be improved, and production cost is reduced; a hydrochloric acid solution is added in a rosuvastatin cyclopentyl ester synthesis process toneutralize redundant acid and alkali, so that the generation of the impurities is further reduced; and therefore, high-purity production is achieved.

The invention relates to the technical field of functional polymers, and in particular, relates to a polyamic acid composition and a preparation method thereof. The polyamic acid composition comprises polyamic acid and a bonding additive, the bonding additive is selected from at least one of a pyridine derivative and a pyrimidine derivative, the pyridine ring of the pyridine derivative is optionally monosubstituted or polysubstituted by -NH2, -OH and -CH2OH, and the pyridine ring of the pyrimidine derivative is optionally monosubstituted or polysubstituted by -NH2 and -OH. The polyamide acid composition is prepared by adding the pyridine derivative or the pyrimidine derivative as a bonding aid, and the polyimide composition, a polyimide film and a polyimide copper-clad plate which are prepared by applying the polyamide acid composition and have high bonding strength are provided, so that the bonding force of polyimide and a copper surface is remarkably improved, the polyimide can be used as an interlayer dielectric material in wafer-level fan-out type packaging or large-board-level fan-out type packaging of high-frequency communication, and thus the problem of low binding force between a current polyamide acid glue solution for a rewiring layer and copper is solved.

The invention discloses an organic compound and an organic electroluminescent device thereof. The organic compound is shown as a formula I, wherein X is oxygen or sulfur; a1 and A2 are respectively and independently selected from hydrogen, alkyl with 1 to 10 carbon atoms, aryl with 6 to 20 carbon atoms or heteroaryl with 5 to 20 carbon atoms; r1 and R2 are respectively and independently selected from carbazolyl containing a substituent group or not containing a substituent group, triazinyl containing a substituent group or not containing a substituent group, pyrimidinyl containing a substituent group or not containing a substituent group, and a group formed by removing one hydrogen from a structure shown in a formula 1 to a formula 9; l1 is absent or selected from an arylene group or a heteroarylene group; l2 is absent or selected from an arylene group or a heteroarylene group. The organic compound provided by the invention has the advantages of low driving voltage and high current efficiency when applied to the organic electroluminescent device.

The invention relates to a preparation method of a pyrimidinylthiobenzoic acid herbicide intermediate, in particular to a synthesis method of a 7-mercaptoisobenzofuran-1(3H)-one compound, and belongsto the technical field of pesticide synthesis. According to the method, the reaction steps are shortened, two-step reaction is changed into one-step reaction, and production operation and energy consumption are reduced. In the production process, the step of catalytic hydrogenation is omitted, and potential safety hazards existing in production are avoided; diazotization and sulfhydrylation stepsare omitted, so that the output of three wastes is reduced; cheap and easily available alkali metal sulfide or alkali metal hydrosulfide and elemental sulfur are used, so that the process route cost is lower, and the method is more suitable for industrial production; under the condition that elemental sulfur is not used, the yield of a target product can reach 80% or above; and under the conditionthat elemental sulfur is used, the yield of a target object can reach 85% or above and even reach 99% and is higher than that of an existing route, the purity is high, and the production cost is further reduced.

The invention relates to the technical field of organic synthesis. In order to solve the problems that an existing palbociclib intermediate, especially a compound with a pyrido[2,3-d]pyrimidine-7-oneskeleton structure, is high in 6-site cyanation reaction cost and low in yield, and cyanide ions harmful to human bodies and the environment can be generated, the invention provides a method for preparing heteroaryl cyanide through the cyanation reaction of the compound. According to the method, a non-toxic cyanation reagent, potassium hexacyanoferrate (K4[Fe(CN)6]), is used as a cyanogen source,and efficient conversion is realized under the catalytic action of bis[2-(diphenylphosphinyl)phenyl]ether palladium chloride (PdCl2(DPEPhos)). The method has the advantages of low cost, greenness, environmental protection, milder reaction conditions and higher yield. Cyanide ions harmful to the human body and the environment are not generated in the post-treatment process of the reaction, so thatthe method has important significance for research and industrial development in pharmacy and related fields.

The invention relates to the field of medical intermediates, and particularly discloses a production process of 4-chloropyrrolo[2,3-d]pyrimidine, which comprises the following steps: S1, adding a compound I and a compound II into a mixed solvent I, and carrying out heating reaction under the catalysis of alkali I to obtain a compound III; and S2, adding sodium alkoxide I into an alcohol solvent II, adding a compound IV and a compound III for a heating reaction, and adding an organic solvent III, an organic solvent IV and a compound V for a heating reaction, so as to obtain a 4-chloropyrrolo [2, 3-d] pyrimidine crude product, wherein the compound I is shown in the specification, the compound II is shown in the specification, the compound III is shown in the specification, the compound IV is formamidine acetate, and the compound V is POCl3. According to the preparation method, he bromo-acetaldehyde dimethyl acetal and ethyl cyanoacetate are subjected to a reflux reaction, and prepared ethyl 2-cyano-4,4-methoxybutyrate and the formamidine acetate are subjected to one-pot chlorination reaction, so that the reaction period is greatly shortened.

The present invention is directed to cocrystal forms of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxcyclopentyl) methyl sulfamate of formula (I). The invention is also directed to methods of making cocrystal forms of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl) methyl sulfamate of formula (I). The invention is also directed to the pharmaceutical use of a cocrystal form as an E1 activating enzyme inhibitor, as well as a pharmaceutical composition comprising a cocrystal form. The invention is further directed to a method of treatment comprising administering a cocrystal form of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate of formula (I).